Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

Sanofi and Regeneron have scored a major victory ... of the drug's price based on ODYSSEY OUTCOMES. The hope is that the new data, coupled with a flexible approach to pricing, will boost sales ...